<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:mp ids='MP_0002055'>Diabetes</z:mp> is associated with increased <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk </plain></SENT>
<SENT sid="1" pm="."><plain>The underlying mechanisms remain unclear </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0003074'>Hyperglycemia</z:hpo> might be one risk factor </plain></SENT>
<SENT sid="3" pm="."><plain>HbA1c is an indicator of the blood <z:chebi fb="105" ids="17234">glucose</z:chebi> level over the latest 1 to 3 months </plain></SENT>
<SENT sid="4" pm="."><plain>This study aimed to investigate association between HbA1c level and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risks in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> based on real life situations </plain></SENT>
<SENT sid="5" pm="."><plain>METHODS: This is a cohort study on 25,476 patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> registered in the Swedish National <z:mp ids='MP_0002055'>Diabetes</z:mp> Register from 1997-1999 and followed until 2009 </plain></SENT>
<SENT sid="6" pm="."><plain>Follow-up for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> was accomplished through register linkage </plain></SENT>
<SENT sid="7" pm="."><plain>We calculated incidences of and hazard ratios (HR) for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in groups categorized by HbA1c ≤ 58 mmol/mol (7.5%) versus &gt;58 mmol/mol, by quartiles of HbA1c, and by HbA1c continuously at Cox regression, with covariance adjustment for age, sex, <z:mp ids='MP_0002055'>diabetes</z:mp> duration, smoking and insulin treatment, or adjusting with a propensity score </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: Comparing HbA1c &gt;58 mmol/mol with ≤ 58 mmol/mol, adjusted HR for <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> was 1.02 [95% CI 0.95-1.10] using baseline HbA1c, and 1.04 [95% CI 0.97-1.12] using updated mean HbA1c, and HRs were <z:hpo ids='HP_0000001'>all</z:hpo> non-significant for specific <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> of gastrointestinal, kidney and urinary organs, respiratory organs, female genital organs, breast or prostate </plain></SENT>
<SENT sid="9" pm="."><plain>Similarly, no increased risks of <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> or the specific types of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> were found with higher quartiles of baseline or updated mean HbA1c, compared to the lowest quartile </plain></SENT>
<SENT sid="10" pm="."><plain>HR for <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> was 1.01 [0.98-1.04] per 1%-unit increase in HbA1c used as a continuous variable, with non-significant HRs also for the specific types of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> per unit increase in HbA1c </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: In this study there were no associations between HbA1c and risks for <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> or specific types of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>